Watchlist Price Alert

Cigna Corporation (CI)

NYSE: CI · Real-Time Price · USD

319.75

-0.64 (-0.20%)

At close: Jul 03, 2025, 3:59 PM

-0.20% (1D)

Bid	299
Market Cap	85.42B
Revenue (ttm)	254.47B
Net Income (ttm)	5.03B
EPS (ttm)	17.93
PE Ratio (ttm)	17.83
Forward PE	9.69
Analyst	Buy

Ask	321.75
Volume	852,424
Avg. Volume (20D)	1,885,168
Open	320.34
Previous Close	320.39
Day's Range	318.68 - 323.10
52-Week Range	262.03 - 370.83
Beta	0.45

About CI

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CI

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Cigna Corporation is scheduled to release its earnings on Jul 31, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+4.43%

Shares of health insurers are trading higher as a ... Unlock content with Pro Subscription

1 month ago

-1.39%

Shares of health insurance stocks are trading lower after CMS announced a strategy to enhance and accelerate Medicare Advantage audits.

News

4 days ago · zacks.com

Cigna Expands Coverage With RhinAer & Enhances Rhinitis Treatment

CI to cover RhinAer for chronic rhinitis starting Sept. 15, expanding access to a minimally invasive, office-based treatment.

6 days ago · businesswire.com

Cigna Enables Coverage for RhinAer®

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced that Cigna Healthcare will provide coverage for RhinA...

1 week ago · zacks.com

4 HMO Stocks Set to Thrive From Steady Premium Flows, M&A Strategy

Rising premiums, ongoing technological innovation and the growing demand for Medicare plans are anticipated to propel the performance of the Zacks Medical-HMO industry players. CI, HUM, CNC and MOH ar...

1 week ago · reuters.com

Cigna sues Bristol Myers over alleged monopoly for multiple myeloma drug Pomalyst

Cigna sued Bristol Myers on Tuesday, accusing the drugmaker of violating federal antitrust law by maintaining a monopoly over a blockbuster multiple myeloma drug sold under the brand name Pomalyst.

1 week ago · reuters.com

US health chief Kennedy met with insurers on prior authorization requirements

U.S. health secretary Robert F. Kennedy Jr. met with major health insurers on Monday, extracting pledges that they will take additional measures to simplify their requirements for prior approval on me...

2 weeks ago · seekingalpha.com

Cigna: Valuation Discount To Historical And Sector Averages Persists

Cigna has transformed into a diversified healthcare platform, focusing on high-margin corporate insurance and pharmacy services while divesting non-core assets. Despite margin pressures, Cigna's servi...

2 weeks ago · seekingalpha.com

Wake Up Wall Street - 2 Massively Mispriced Dividend Gems

I believe the odds favor long-term market gains. Analysts' optimism supports my view that overlooked areas offer the best opportunities now. That's why I'm focusing on two dividend stocks with rising ...